The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to analyze 161 of the most relevant cancer driver genes. This panel facilitates the detection of actionable mutations in solid tumor cancers, including lung cancer, colorectal cancer, skin cancer (melanoma), breast cancer, brain cancer, and thyroid cancer.
|Highly accurate||>99% sensitivity and specificity*|
|Comprehensive||>99% of guideline-recommended genes tested|
|Actionable||Delivers insights to guide targeted therapy or clinical trial selection|
|Advanced||Powered by the Oncomine platform, a next-generation sequencing solution used by leading global research institutions and clinical trials, including the NCI-MATCH trial|
*Compared against a series of cases with known or previously-tested mutations by other NGS methods.
Powerful insights to help personalize treatment
This test is designed to help identify appropriate targeted therapies and clinical trials to facilitate first-line treatment selection or later-line care decisions. The Solid Tumor Panel tests for clinically significant mutations in solid tumor cancers, including
|12 genes found in 19 guidelines for solid tumor genetic testing||117 genes included in 800+ clinical trials worldwide||9 genes associated with 36 targeted therapies approved by the FDA|
Analyzes 161 of the most relevant cancer driver genes
Genes interrogated by the Solid Tumor Panel
|Hotspot regions sequenced 87 genes||AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1|
|All coding exons sequenced 48 genes||ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2|
|Copy number variations queried 43 genes||AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT|
|Rearrangements or fusions queried 51 genes||AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT|
Results are presented in a comprehensive report
- Depending on the case and findings, the report provides insight into
- Appropriate targeted therapies and clinical trials
- Resistance markers
- Clinically relevant negative results
- Patient prognosis
We are dedicated to helping every patient access advanced genetic testing
Sema4 is contracted with all major national payors. For patients who are uninsured or underinsured, affordable payment plans, self-pay pricing, and other financial assistance options are also available. To learn more, please contact our billing specialists at firstname.lastname@example.org or 800-298-6470.
Oncomine is a trademark of Thermo Fisher Scientific Inc. All rights reserved. No clinical claims, sponsorship, endorsement, or affiliation by Thermo Fisher Scientific is implied herein. The data generated by Sema4 is the sole responsibility of Sema4. The Oncomine Comprehensive Tumor Profiling Assay was developed by leading cancer institutes and regulatory agencies, and distributed by Thermo Fisher to support the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial. To learn more, please see Lih CJ, Harrington RD, Sims DJ, et al. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017; 19: 313-327.